Copyright
©The Author(s) 2019.
World J Gastroenterol. May 7, 2019; 25(17): 2045-2057
Published online May 7, 2019. doi: 10.3748/wjg.v25.i17.2045
Published online May 7, 2019. doi: 10.3748/wjg.v25.i17.2045
Table 2 Univariate analyses for each risk factors progression to high grade dysplasia or esophageal adenocarcinoma[4]
Variable | Adjusted P value and hazard ratios (95%CI) |
Males | P = 0.0023, HR = 3.01 (1.48-6.11) |
Smoking | P = 0.0029, HR = 1.83 (1.23-2.71) |
Age + 10 yr | P = 0.3055, HR = 0.96 (0.89-1.04) |
Caucasian | P = 0.8429, HR = 1.06 (0.61-1.82) |
Hiatal hernia present | P = 0.5928, HR = 1.12 (0.73-1.72) |
Visible lesion at baseline | P = 0.9254, HR = 1.04 (0.49-2.2) |
Aspirin use | P = 0.2807, HR = 0.81 (0.56-1.18) |
Non-steroidal anti-inflammatory drug | P = 0.5602, HR = 0.9 (0.64-1.28) |
Proton pump inhibitor | P = 0.8197, HR = 0.9 (0.37-2.21) |
Low grade dysplasia | P ≤ 0.0001, HR = 3.68 (2.56-5.31) |
BE length + 1 cm increase in length | P ≤ 0.0001, HR = 1.12 (1.08-1.18) |
- Citation: Steele D, Baig KKK, Peter S. Evolving screening and surveillance techniques for Barrett's esophagus. World J Gastroenterol 2019; 25(17): 2045-2057
- URL: https://www.wjgnet.com/1007-9327/full/v25/i17/2045.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i17.2045